Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
It is hypothesized that early changes in the immune system in New Onset Type 1 Diabetes Mellitus (NOT1D) subjects can be detected in immune cells from the inguinal lymph nodes (iLN), which will be distinct from changes observed in peripheral blood derived immune cells. Therefore this study will assess and compare the molecular immune profile of cells derived from the iLN in healthy and NOT1D subjects, to understand the immunological processes that may lead to beta cell destruction. It is a multi-center, non-drug treatment study. Up to 15 subjects in each group, namely healthy subjects and NOT1D subjects, will be evaluated in the study. A data look will be carried out after the recruitment of a cohort of up to 5 healthy subjects, to determine if the quality and quantity of cells derived from aspirate or core biopsy or from peripheral blood are likely to be sufficient to continue the study to meet its primary objective. An interim analysis will be carried out after the recruitment of 5 evaluable healthy subjects and 5 evaluable NOT1D subjects. The primary purpose of this interim analysis will be to facilitate decision making and study design for a potential follow-up interventional study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy subjects | Experimental | Up to 30 mL of blood sample will be collected from healthy subjects. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, Human Leukocyte antigen D related (HLA-DR) and forkhead box P3 protein also called scurfin (FOXP3). |
|
| Subjects with NOT1D | Experimental | Up to 30 mL of blood sample will be collected from subjects with NOT1D. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, HLA-DR and FOXP3. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Inguinal lymph node fine needle aspirate biopsy | Procedure | Inguinal lymph node will be localized by ultrasonography and sampled by 21-gauge needle and a 5 mL syringe using to and fro needle movement while applying 1 mL suction with the syringe. Up to 2 fine needle aspirate passages will be obtained, to derive immune cells. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B Lymphocytes in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. The analysis was based upon Safety Population which comprised of all participants who complete any study assessment. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Pre Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B Lymphocytes in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including B-cells, Clusters of Differentiation 56 Positive (CD56+) CD16+ , CD56bright Natural Killer (NK) Cells, CD56lo CD16+, CD56lo CD16 Negative (CD56lo CD16-), Dendritic Cells, NK Cells in Blood |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B Lymphocytes in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | GlaxoSmithKline | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GSK Investigational Site | Cambridge | CB2 0QQ | United Kingdom | |||
| GSK Investigational Site |
Participants underwent iLN biopsies by two methods; fine-needle aspirate (FNA) and core needle biopsy. Participants underwent screening followed by study visits and follow-up. A total of 43 participants were screened, of which, 21 were considered as screen failures and 22 were enrolled into the study.
This was a multi-center, non-drug treatment study to compare differences in immune cells derived from the inguinal lymph nodes (iLN) and peripheral blood of New Onset Type 1 Diabetes Mellitus (NOT1D) participants and healthy volunteers. Participants were enrolled at a single center in United Kingdom.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Healthy Participants | Participants were considered healthy if values for the following parameters: fasted glucose, glycated hemoglobin, International normalized ratio (INR), activated partial thromboplastin time (APTT), platelet count, red blood cells and total lymphocyte count were within the normal range at screening. |
| FG001 | Participants With NOT1D | NOT1D participants with documented diagnosis of diabetes mellitus according to American Diabetes Association (ADA) and World Health Organization (WHO) criteria and consistent with Type 1a (autoimmune) Diabetes Mellitus, were included in the study. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Healthy Participants | Participants were considered healthy if values for the following parameters: fasted glucose, glycated hemoglobin, International normalized ratio (INR), activated partial thromboplastin time (APTT), platelet count, red blood cells and total lymphocyte count were within the normal range at screening. |
| BG001 |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B Lymphocytes in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. The analysis was based upon Safety Population which comprised of all participants who complete any study assessment. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of B lymphocytes | Pre Biopsy session on Day 1 |
Serious adverse events (SAEs) and non-serious adverse events (non-SAEs) were collected up to Day 14.
SAEs and Non-SAEs were reported for Safety Population which comprised of all participants who completed any study assessment.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Healthy Participants | Participants were considered healthy if values for the following parameters: fasted glucose, glycated hemoglobin, International normalized ratio (INR), activated partial thromboplastin time (APTT), platelet count, red blood cells and total lymphocyte count were within the normal range at screening. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nausea | Gastrointestinal disorders | MedDRA 20.1 | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| GSK Response Center | GlaxoSmithKline | 866-435-7343 | GSKClinicalSupportHD@gsk.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Mar 6, 2017 | Jun 20, 2018 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jun 9, 2017 | Jun 20, 2018 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D003922 | Diabetes Mellitus, Type 1 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D007854 | Lead |
| ID | Term |
|---|---|
| D019216 | Metals, Heavy |
| D004602 | Elements |
| D007287 | Inorganic Chemicals |
| D008670 | Metals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Inguinal lymph node core biopsy | Procedure | Inguinal lymph node will be localized by ultrasonography and following fine needle aspirate, an incision will be made. Up to five core biopsies will be obtained, to derive immune cells. |
|
| Peripheral blood collection | Procedure | Blood sample (30 mL) will be collected, to derive immune cells. |
|
| Pre- and post-biopsy questionnaire | Other | All subjects will be asked to complete a questionnaire about their expectations/experiences of undergoing the biopsy procedures. |
|
Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. NA indicates that data was not available. |
| Pre Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including B-cells, CD56+ CD16+, CD56bright NK Cells, CD56lo CD16+, CD56lo CD16-, Dendritic Cells, NK Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD56+CD16+, CD56bright NK Cells, CD56lo CD16+ and CD56lo CD16- in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. NA indicates that data was not available. | Pre Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD56+CD16+, CD56bright NK Cells CD56lo CD16+ and CD56lo CD16- in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including Myeloid Dendritic Cells and Plasmacytoid Dendritic Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Pre Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including Myeloid Dendritic Cells and Plasmacytoid Dendritic Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA.Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD14+ CD16+ Monocytes, CD14+ Monocytes, and CD16+ Monocytes in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. NA indicates that data was not available. | Pre Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD14+ CD16+ Monocytes, CD14+ Monocytes and CD16+ Monocytes in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD45RA+ Effector Memory CD8, Central Memory CD8, Effector Memory CD8, Naive CD8 and Stem Cell Memory-like CD8 Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Pre Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD45RA+ Effector Memory CD8, Central Memory CD8, Effector Memory CD8, Naive CD8 and Stem Cell Memory-like CD8 Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including Programmed Death 1 (PD-1)+ Inducible Costimulator (ICOS)+ Follicular Helper T (TFH) Cell-like Regulatory (Reg) T Cells in Blood | Peripheral blood samples were planned to be collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T cell Panel. Results could not be presented as data were not collected for this analysis due to lack of model convergence or model reliability | Pre Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cell-like Reg T Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. NA indicates that data was not available. | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Pre Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including Central Memory Conventional (Conv) T Cells, Effector Memory Conv T Cells, Naive Conv T Cells and Stem Cell Memory-like Conv T Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Pre Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including Central Memory Conv T Cells, Effector Memory Conv T Cells, Naive Conv T Cells and Stem Cell Memory-like Conv T Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, Type 17 T Helper (TH17) Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 T Cells, TH1 TH2 Cells, TH2 Cells, and TH22 Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Pre Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, Type 17 T Helper (TH17) Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 T Cells, TH1 TH2 Cells, TH2 Cells, and TH22 Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 Cells, TH1 TH2 Cells, TH17 Cells, TH2 Cells and TH22 Cells-like Reg T Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. NA indicates that data was not availble. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Pre Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 Cells, TH1 TH2 Cells, TH17 Cells, TH2 Cells and TH22 Cells-like Reg T Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including Reg T Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Pre Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including Reg T Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD69+ CD8 and Antigen Ki67 (Ki67)+ CD8 in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Pre Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD69+ CD8 and Antigen Ki67 (Ki67)+ CD8 in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD15s+ Reg T Cells, CD69+ Reg T Cells, Helios+ Reg T Cells, Ki67+ T Reg Cells, Memory Reg T Cells and Resting Reg T Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Pre Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD15s+ Reg T Cells, CD69+ Reg T Cells, Helios+ Reg T Cells, Ki67+ T Reg Cells, Memory Reg T Cells and Resting Reg T Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD15s+ Conv T Cells, CD69+ Conv T Cells, Helios+ Conv T Cells and Ki67+ Conv T Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Pre Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD15s+ Conv T Cells, CD69+ Conv T Cells, Helios+ Conv T Cells and Ki67+ Conv T Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Pre Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Biopsy session on Day 1 |
| Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including B-cells, CD56+ CD16+, CD56bright NK Cells, CD56lo CD16+, CD56lo CD16, Dendritic Cells, NK Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD56+CD16+, CD56br NK Cells CD56lo CD16+ and CD56lo CD16- in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including Myeloid Dendritic Cells and Plasmacytoid Dendritic Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD14+ CD16+ Monocytes, CD14+ Monocytes and CD16+ Monocytes in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates data was not available. | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD45RA+ Effector Memory CD8, Central Memory CD8, Effector Memory CD8, Naive CD8 and Stem Cell Memory-like CD8 in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cell-like Reg T Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including Central Memory Conv T Cells, Effector Memory Conv T Cells, Naive Conv T Cells and Stem Cell Memory-like Conv T Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH17 Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 T Cells, TH1 TH2 Cells, TH2 Cells, and TH22 Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 Cells, TH1 TH2 Cells, TH17 Cells, TH2 Cells and TH22 Cells-like Reg T Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including Reg T Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD69+ CD8 and Antigen Ki67 (Ki67)+ CD8 in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD15s+ Reg T Cells, CD69+ Reg T Cells, Helios+ Reg T Cells, Ki67+ T Reg Cells, Memory Reg T Cells and Resting Reg T Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD15s+ Conv T Cells, CD69+ Conv T Cells, Helios+ Conv T Cells and Ki67+ Conv T Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Biopsy session on Day 1 |
| Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Biopsy session on Day 1 |
| Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/ incapacity, is a congenital anomaly/ birth defect or other situations. | Up to Day 14 |
| Number of Participants Undergoing Procedure Under Local Anesthetics | Participants were asked to complete Pre-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. The number of participants who underwent procedure under local anesthetics have been presented. | Up to Day 4 |
| Number of Participants Undergoing iLN Biopsy Under Local Anesthetics | Participants were asked to complete Pre-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. The number of participants who underwent iLN biopsy under local anesthetics have been presented. | Up to Day 4 |
| Number of Participants With Different Reasons for Participating in the Study | Participants were asked to complete Pre-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. The different reasons have been listed as follows; have friend with diabetes mellitus (DM)/ to progress knowledge, to improve medicines development, participating in the study because of the honorarium, any other reason not listed above was categorized as "other" and participants having all three reasons as listed above to participate in the study were included in "All reasons" category | Up to Day 4 |
| Number of Participants With Extreme Anxiety Towards the Lymph Node Biopsy | Participants were asked to complete Pre-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. The number of participants with extreme anxiety towards the procedure have been presented. | Up to Day 4 |
| Number of Participants Looking Forward to Undergo the Procedure | Participants were asked to complete Pre-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. The number of participants looking forward to undergo the procedure have been presented. | Up to Day 4 |
| Number of Participants With Aspects Better Explained About the Lymph Node Biopsy Procedure | Participants were asked to complete Post-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. The aspects better explained were as follows; itself, anesthetic procedure, after-care, none and any other procedure not listed above was categorized as "other". | Up to Day 4 |
| Number of Participants Who Considered to Undergo Lymph Node Biopsy Procedure Another Time | Participants were asked to complete Post-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. The number of participants who considered to undergo procedure another time have been presented. | Up to Day 4 |
| Number of Participants Who Were Encouraged to be Included in Study for iLN Biopsy | Participants were asked to complete Post-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. Participants who were encouraged in study for iLN biopsy have been presented. | Up to Day 4 |
| Number of Participants Who Appreciated Receiving Study Feedback | Participants were asked to complete Post-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. Participants who appreciated receiving study feedback have been presented. | Up to Day 4 |
| Cardiff |
| CF14 4XN |
| United Kingdom |
| Participants With NOT1D |
NOT1D participants with documented diagnosis of diabetes mellitus according to American Diabetes Association (ADA) and World Health Organization (WHO) criteria and consistent with Type 1a (autoimmune) Diabetes Mellitus, were included in the study. |
| BG002 | Total | Total of all reporting groups |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| ID | Title | Description |
|---|
| OG000 | Healthy Participants | Participants were considered healthy if values for the following parameters: fasted glucose, glycated hemoglobin, International normalized ratio (INR), activated partial thromboplastin time (APTT), platelet count, red blood cells and total lymphocyte count were within the normal range at screening. |
| OG001 | Participants With NOT1D | NOT1D participants with documented diagnosis of diabetes mellitus according to American Diabetes Association (ADA) and World Health Organization (WHO) criteria and consistent with Type 1a (autoimmune) Diabetes Mellitus, were included in the study. |
|
|
|
| Primary | Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B Lymphocytes in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of B lymphocytes | Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including B-cells, Clusters of Differentiation 56 Positive (CD56+) CD16+ , CD56bright Natural Killer (NK) Cells, CD56lo CD16+, CD56lo CD16 Negative (CD56lo CD16-), Dendritic Cells, NK Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. NA indicates that data was not available. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of mononuclear cells | Pre Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including B-cells, CD56+ CD16+, CD56bright NK Cells, CD56lo CD16+, CD56lo CD16-, Dendritic Cells, NK Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of mononuclear cells | Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including CD56+CD16+, CD56bright NK Cells, CD56lo CD16+ and CD56lo CD16- in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. NA indicates that data was not available. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of NK cells | Pre Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including CD56+CD16+, CD56bright NK Cells CD56lo CD16+ and CD56lo CD16- in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of NK cells | Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including Myeloid Dendritic Cells and Plasmacytoid Dendritic Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of total dendritic cells | Pre Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including Myeloid Dendritic Cells and Plasmacytoid Dendritic Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA.Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of total dendritic cells | Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including CD14+ CD16+ Monocytes, CD14+ Monocytes, and CD16+ Monocytes in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. NA indicates that data was not available. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of monocytes | Pre Biopsy session on Day 1 |
|
|
|
| Primary | Percentage of Leukocyte Subsets Including CD14+ CD16+ Monocytes, CD14+ Monocytes and CD16+ Monocytes in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of monocytes | Biopsy session on Day 1 |
|
|
|
| Primary | Percentage of Leukocyte Subsets Including CD45RA+ Effector Memory CD8, Central Memory CD8, Effector Memory CD8, Naive CD8 and Stem Cell Memory-like CD8 Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of CD8 T cells | Pre Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including CD45RA+ Effector Memory CD8, Central Memory CD8, Effector Memory CD8, Naive CD8 and Stem Cell Memory-like CD8 Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of CD8 T cells | Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including Programmed Death 1 (PD-1)+ Inducible Costimulator (ICOS)+ Follicular Helper T (TFH) Cell-like Regulatory (Reg) T Cells in Blood | Peripheral blood samples were planned to be collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T cell Panel. Results could not be presented as data were not collected for this analysis due to lack of model convergence or model reliability | Safety Population. Data were not collected due to lack of model convergence or model reliability. | Posted | Pre Biopsy session on Day 1 |
|
|
| Primary | Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cell-like Reg T Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. NA indicates that data was not available. | Safety Population. Only those participants with data available at specified time point were analyzed. | Posted | Least Squares Mean | Standard Error | Percentage of TFH cell-like Reg T cells | Biopsy session on Day 1 |
|
|
|
| Primary | Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Safety Population. Only those participants with data available at specified time point were analyzed. | Posted | Least Squares Mean | Standard Error | Percentage of TFH cells | Pre Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Safety Population. Only those participants with data available at specified time point were analyzed. | Posted | Least Squares Mean | Standard Error | Percentage of TFH cells | Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including Central Memory Conventional (Conv) T Cells, Effector Memory Conv T Cells, Naive Conv T Cells and Stem Cell Memory-like Conv T Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of total Conv T cells | Pre Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including Central Memory Conv T Cells, Effector Memory Conv T Cells, Naive Conv T Cells and Stem Cell Memory-like Conv T Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of total Conv T cells | Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, Type 17 T Helper (TH17) Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 T Cells, TH1 TH2 Cells, TH2 Cells, and TH22 Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of total memory Conv T cells | Pre Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, Type 17 T Helper (TH17) Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 T Cells, TH1 TH2 Cells, TH2 Cells, and TH22 Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percenatge of total memory Conv T cells | Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 Cells, TH1 TH2 Cells, TH17 Cells, TH2 Cells and TH22 Cells-like Reg T Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. NA indicates that data was not availble. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of total memory Reg T cells | Pre Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 Cells, TH1 TH2 Cells, TH17 Cells, TH2 Cells and TH22 Cells-like Reg T Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of total memory Reg T cells | Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including Reg T Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of CD4 T cells | Pre Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including Reg T Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Safety Population. Only those participants with data available at specified time point were analyzed. | Posted | Least Squares Mean | Standard Error | Percentage of CD4 T cells | Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including CD69+ CD8 and Antigen Ki67 (Ki67)+ CD8 in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of CD8 T cells | Pre Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including CD69+ CD8 and Antigen Ki67 (Ki67)+ CD8 in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of CD8 T cells | Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including CD15s+ Reg T Cells, CD69+ Reg T Cells, Helios+ Reg T Cells, Ki67+ T Reg Cells, Memory Reg T Cells and Resting Reg T Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of T Reg cells | Pre Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including CD15s+ Reg T Cells, CD69+ Reg T Cells, Helios+ Reg T Cells, Ki67+ T Reg Cells, Memory Reg T Cells and Resting Reg T Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of T Reg cells | Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including CD15s+ Conv T Cells, CD69+ Conv T Cells, Helios+ Conv T Cells and Ki67+ Conv T Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of total Conv T cells | Pre Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including CD15s+ Conv T Cells, CD69+ Conv T Cells, Helios+ Conv T Cells and Ki67+ Conv T Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of total Conv T cells | Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in Blood | Peripheral blood samples were collected from both healthy and NOT1D participants at the indicated time points for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of total memory Conv T cells | Pre Biopsy session on Day 1 |
|
|
|
|
| Primary | Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in iLN | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of total memory Conv T cells | Biopsy session on Day 1 |
|
|
|
|
| Secondary | Percentage of Leukocyte Subsets Including B Lymphocytes, Classical B Lymphocytes, Double Negative B Lymphocytes, Naive B Lymphocytes, Plasmablast and Transitional B Lymphocytes in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of B lymphocytes | Biopsy session on Day 1 |
|
|
|
|
| Secondary | Percentage of Leukocyte Subsets Including B-cells, CD56+ CD16+, CD56bright NK Cells, CD56lo CD16+, CD56lo CD16, Dendritic Cells, NK Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of mononuclear cells | Biopsy session on Day 1 |
|
|
|
|
| Secondary | Percentage of Leukocyte Subsets Including CD56+CD16+, CD56br NK Cells CD56lo CD16+ and CD56lo CD16- in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of NK cells | Biopsy session on Day 1 |
|
|
|
|
| Secondary | Percentage of Leukocyte Subsets Including Myeloid Dendritic Cells and Plasmacytoid Dendritic Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of total dendritic cells | Biopsy session on Day 1 |
|
|
|
|
| Secondary | Percentage of Leukocyte Subsets Including CD14+ CD16+ Monocytes, CD14+ Monocytes and CD16+ Monocytes in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from Monocyte Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates data was not available. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of monocytes | Biopsy session on Day 1 |
|
|
|
| Secondary | Percentage of Leukocyte Subsets Including CD45RA+ Effector Memory CD8, Central Memory CD8, Effector Memory CD8, Naive CD8 and Stem Cell Memory-like CD8 in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of CD8 T cells | Biopsy session on Day 1 |
|
|
|
|
| Secondary | Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cell-like Reg T Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of TFH cell-like Reg T Cells | Biopsy session on Day 1 |
|
|
|
| Secondary | Percentage of Leukocyte Subsets Including PD-1+ ICOS+ TFH Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of TFH cells | Biopsy session on Day 1 |
|
|
|
|
| Secondary | Percentage of Leukocyte Subsets Including Central Memory Conv T Cells, Effector Memory Conv T Cells, Naive Conv T Cells and Stem Cell Memory-like Conv T Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of total Conv T cell | Biopsy session on Day 1 |
|
|
|
|
| Secondary | Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH17 Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 T Cells, TH1 TH2 Cells, TH2 Cells, and TH22 Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percenatge of total memory Conv T cells | Biopsy session on Day 1 |
|
|
|
|
| Secondary | Percentage of Leukocyte Subsets Including TFH Cells, PD-1+ ICOS+ TFH Cells, TH1 Cells, TH1 TH17 Cells, TH1 TH17 TH2 Cells, TH1 TH2 Cells, TH17 Cells, TH2 Cells and TH22 Cells-like Reg T Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). NA indicates that data was not available. | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of total memory Reg T cells | Biopsy session on Day 1 |
|
|
|
|
| Secondary | Percentage of Leukocyte Subsets Including Reg T Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of CD4 T cells | Biopsy session on Day 1 |
|
|
|
|
| Secondary | Percentage of Leukocyte Subsets Including CD69+ CD8 and Antigen Ki67 (Ki67)+ CD8 in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of CD8 T cells | Biopsy session on Day 1 |
|
|
|
|
| Secondary | Percentage of Leukocyte Subsets Including CD15s+ Reg T Cells, CD69+ Reg T Cells, Helios+ Reg T Cells, Ki67+ T Reg Cells, Memory Reg T Cells and Resting Reg T Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of T Reg cells | Biopsy session on Day 1 |
|
|
|
|
| Secondary | Percentage of Leukocyte Subsets Including CD15s+ Conv T Cells, CD69+ Conv T Cells, Helios+ Conv T Cells and Ki67+ Conv T Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of total Conv T cells | Biopsy session on Day 1 |
|
|
|
|
| Secondary | Percentage of Leukocyte Subsets Including CD15s+ Memory Conv T Cells, CD69+ Memory Conv T Cells, Helios+ Memory Conv T Cells and Ki67+ Memory Conv T Cells in iLN Core Biopsies and iLN FNA | Samples were collected including up to two FNA passages of iLN and up to five core biopsies of iLN at the indicated time point from both healthy and NOT1D participants for the analysis of leukocyte subsets from T Reg cell Panel. Candidate biomarkers associated with either location of cells and/or disease-status were identified using flow cytometry technique. Generalized linear mixed models were used to analyze data separately for each flow cytometry cell type to provide estimates for comparisons. Fixed categorical were group, sample type, and the interaction of group with sample type, where Group was HV or NOT1D, and sample type was peripheral blood, core biopsy or FNA. Only those participants with data available at specific time point were analyzed (represented by n=x in category titles). | Safety Population | Posted | Least Squares Mean | Standard Error | Percentage of total memory Conv cells | Biopsy session on Day 1 |
|
|
|
|
| Secondary | Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/ incapacity, is a congenital anomaly/ birth defect or other situations. | Safety Population | Posted | Count of Participants | Participants | Up to Day 14 |
|
|
|
| Secondary | Number of Participants Undergoing Procedure Under Local Anesthetics | Participants were asked to complete Pre-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. The number of participants who underwent procedure under local anesthetics have been presented. | Safety Population | Posted | Count of Participants | Participants | Up to Day 4 |
|
|
|
| Secondary | Number of Participants Undergoing iLN Biopsy Under Local Anesthetics | Participants were asked to complete Pre-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. The number of participants who underwent iLN biopsy under local anesthetics have been presented. | Safety Population | Posted | Count of Participants | Participants | Up to Day 4 |
|
|
|
| Secondary | Number of Participants With Different Reasons for Participating in the Study | Participants were asked to complete Pre-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. The different reasons have been listed as follows; have friend with diabetes mellitus (DM)/ to progress knowledge, to improve medicines development, participating in the study because of the honorarium, any other reason not listed above was categorized as "other" and participants having all three reasons as listed above to participate in the study were included in "All reasons" category | Safety Population | Posted | Count of Participants | Participants | Up to Day 4 |
|
|
|
| Secondary | Number of Participants With Extreme Anxiety Towards the Lymph Node Biopsy | Participants were asked to complete Pre-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. The number of participants with extreme anxiety towards the procedure have been presented. | Safety Population | Posted | Count of Participants | Participants | Up to Day 4 |
|
|
|
| Secondary | Number of Participants Looking Forward to Undergo the Procedure | Participants were asked to complete Pre-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. The number of participants looking forward to undergo the procedure have been presented. | Safety Population | Posted | Count of Participants | Participants | Up to Day 4 |
|
|
|
| Secondary | Number of Participants With Aspects Better Explained About the Lymph Node Biopsy Procedure | Participants were asked to complete Post-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. The aspects better explained were as follows; itself, anesthetic procedure, after-care, none and any other procedure not listed above was categorized as "other". | Safety Population | Posted | Count of Participants | Participants | Up to Day 4 |
|
|
|
| Secondary | Number of Participants Who Considered to Undergo Lymph Node Biopsy Procedure Another Time | Participants were asked to complete Post-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. The number of participants who considered to undergo procedure another time have been presented. | Safety Population | Posted | Count of Participants | Participants | Up to Day 4 |
|
|
|
| Secondary | Number of Participants Who Were Encouraged to be Included in Study for iLN Biopsy | Participants were asked to complete Post-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. Participants who were encouraged in study for iLN biopsy have been presented. | Safety Population | Posted | Count of Participants | Participants | Up to Day 4 |
|
|
|
| Secondary | Number of Participants Who Appreciated Receiving Study Feedback | Participants were asked to complete Post-Biopsy Lymph Node Questionnaire about their expectations/experiences of undergoing the procedure of FNA biopsy followed by core needle biopsy. Participants who appreciated receiving study feedback have been presented. | Safety Population | Posted | Count of Participants | Participants | Up to Day 4 |
|
|
|
| 0 |
| 12 |
| 0 |
| 12 |
| 9 |
| 12 |
| EG001 | Participants With NOT1D | NOT1D participants with documented diagnosis of diabetes mellitus according to American Diabetes Association (ADA) and World Health Organization (WHO) criteria and consistent with Type 1a (autoimmune) Diabetes Mellitus, were included in the study. | 0 | 10 | 0 | 10 | 5 | 10 |
| Fatigue | General disorders | MedDRA 20.1 | Systematic Assessment |
|
| Post procedural contusion | Injury, poisoning and procedural complications | MedDRA 20.1 | Systematic Assessment |
|
| Procedural pain | Injury, poisoning and procedural complications | MedDRA 20.1 | Systematic Assessment |
|
GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
| D004700 | Endocrine System Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| Classical B Lymphocytes; n=9, 10 |
|
|
| Double Negative B Lymphocytes; n=9, 10 |
|
|
| Naive B Lymphocytes; n=9, 10 |
|
|
| Plasmablast; n=4, 8 |
|
|
| Transitional B Lymphocytes; ; n=3, 2 |
|
|
| Mean Difference (Final Values) |
| 8.59 |
| Standard Error of the Mean |
| 5.833 |
| 2-Sided |
| 95 |
| -3.72 |
| 20.91 |
The mean difference in Classical B Lymphocytes (Healthy participants versus NOT1D participants) in iLN has been presented. |
| Other |
| Mean Difference (Final Values) | -1.58 | Standard Error of the Mean | 2.347 | 2-Sided | 95 | -6.53 | 3.38 | The mean difference in Double Negative B Lymphocytes (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | -8.31 | Standard Error of the Mean | 5.221 | 2-Sided | 95 | -19.32 | 2.71 | The mean difference in Naive B Lymphocytes (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| CD56bright NK cells |
|
| CD56lo CD16+ |
|
| CD56lo CD16- |
|
| Dendritic cells |
|
| NK cells |
|
| Mean Difference (Final Values) |
| 0.06 |
| Standard Error of the Mean |
| 0.063 |
| 2-Sided |
| 95 |
| -0.07 |
| 0.19 |
The mean difference in CD56bright NK cells (Healthy participants versus NOT1D participants) in blood has been presented. |
| Other |
| Mean Difference (Final Values) | -0.29 | Standard Error of the Mean | 1.500 | 2-Sided | 95 | -3.41 | 2.84 | The mean difference in CD56lo CD16+ (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | 0.02 | Standard Error of the Mean | 0.054 | 2-Sided | 95 | -0.10 | 0.13 | The mean difference in CD56lo CD16- (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | 0.06 | Standard Error of the Mean | 0.118 | 2-Sided | 95 | -0.19 | 0.31 | The mean difference in Dendritic cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | -0.14 | Standard Error of the Mean | 1.482 | 2-Sided | 95 | -3.23 | 2.96 | The mean difference in NK cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| CD56+CD16+; n=8, 8 |
|
|
| CD56bright NK cells; n=9, 10 |
|
|
| CD56lo CD16+; n=9, 10 |
|
|
| CD56lo CD16-; n=8, 9 |
|
|
| Dendritic cells; n=9, 10 |
|
|
| NK cells; n=9, 10 |
|
|
| Mean Difference (Final Values) |
| 0.05 |
| Standard Error of the Mean |
| 0.140 |
| 2-Sided |
| 95 |
| -0.25 |
| 0.34 |
The mean difference in CD56bright sNK cells (Healthy participants versus NOT1D participants) in iLN has been presented. |
| Other |
| Mean Difference (Final Values) | -0.01 | Standard Error of the Mean | 0.253 | 2-Sided | 95 | -0.54 | 0.52 | The mean difference in CD56lo CD16+ (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | -0.02 | Standard Error of the Mean | 0.059 | 2-Sided | 95 | -0.15 | 0.10 | The mean difference in CD56lo CD16- (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | -0.07 | Standard Error of the Mean | 0.128 | 2-Sided | 95 | -0.21 | 0.34 | The mean difference in Dendritic cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | -0.07 | Standard Error of the Mean | 0.487 | 2-Sided | 95 | -1.10 | 0.96 | The mean difference in NK cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| CD56lo CD16+ |
|
| CD56lo CD16- |
|
| Mean Difference (Final Values) |
| -2.69 |
| Standard Error of the Mean |
| 2.324 |
| 2-Sided |
| 95 |
| -7.54 |
| 2.16 |
The mean difference in CD56lo CD16+ (Healthy participants versus NOT1D participants) in blood has been presented. |
| Other |
| Mean Difference (Final Values) | 0.42 | Standard Error of the Mean | 0.738 | 2-Sided | 95 | -1.12 | 1.95 | The mean difference in CD56lo CD16- (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| CD56bright NK cells; n=9, 10 |
|
|
| CD56lo CD16+; n=9, 10 |
|
|
| CD56lo CD16-; n=8, 9 |
|
|
| Mean Difference (Final Values) |
| -7.89 |
| Standard Error of the Mean |
| 7.918 |
| 2-Sided |
| 95 |
| -24.77 |
| 9.00 |
The mean difference in CD56lo CD16+ (Healthy participants versus NOT1D participants) in iLN has been presented. |
| Other |
| Mean Difference (Final Values) | -1.46 | Standard Error of the Mean | 2.379 | 2-Sided | 95 | -6.66 | 3.73 | The mean difference in CD56lo CD16- (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) |
| -1.85 |
| Standard Error of the Mean |
| 4.658 |
| 2-Sided |
| 95 |
| -11.57 |
| 7.86 |
The mean difference in plasmacytoid dendritic cells (Healthy participants versus NOT1D participants) in blood has been presented. |
| Other |
| Plasmacytoid Dendritic cells; n=9, 9 |
|
|
| Mean Difference (Final Values) |
| -10.87 |
| Standard Error of the Mean |
| 6.961 |
| 2-Sided |
| 95 |
| -25.52 |
| 3.78 |
The mean difference in plasmacytoid dendritic cells (Healthy participants versus NOT1D participants) in iLN has been presented. |
| Other |
| CD16+ monocytes |
|
| CD14+ monocytes; n=7, 4 |
|
|
| CD16+ monocytes; n=0, 2 |
|
|
| Effector Memory CD8 |
|
| Naive CD8 |
|
| Stem Cell Memory-like CD8 |
|
| Mean Difference (Final Values) |
| 0.15 |
| Standard Error of the Mean |
| 2.280 |
| 2-Sided |
| 95 |
| -4.60 |
| 4.91 |
The mean difference in Central Memory CD8 (Healthy participants versus NOT1D participants) in blood has been presented. |
| Other |
| Mean Difference (Final Values) | 4.38 | Standard Error of the Mean | 3.297 | 2-Sided | 95 | -2.50 | 11.26 | The mean difference in Effector Memory CD8 (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | -6.06 | Standard Error of the Mean | 5.729 | 2-Sided | 95 | -18.01 | 5.89 | The mean difference in Naive CD8 (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | -0.03 | Standard Error of the Mean | 0.305 | 2-Sided | 95 | -0.67 | 0.60 | The mean difference in Stem Cell Memory-like CD8 (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Effector Memory CD8 |
|
| Naive CD8 |
|
| Stem Cell Memory-like CD8 |
|
| Mean Difference (Final Values) |
| -0.66 |
| Standard Error of the Mean |
| 1.466 |
| 2-Sided |
| 95 |
| -3.73 |
| 2.41 |
The mean difference in Central Memory CD8 (Healthy participants versus NOT1D participants) in iLN has been presented. |
| Other |
| Mean Difference (Final Values) | -1.85 | Standard Error of the Mean | 2.790 | 2-Sided | 95 | -7.67 | 3.96 | The mean difference in Effector Memory CD8 (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | 0.67 | Standard Error of the Mean | 6.342 | 2-Sided | 95 | -12.54 | 13.87 | The mean difference in Naive CD8 (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | -0.67 | Standard Error of the Mean | 0.492 | 2-Sided | 95 | -1.71 | 0.36 | The mean difference in Stem Cell Memory-like CD8 (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Effector Memory Conv T cells |
|
| Naive Conv T cells |
|
| Stem Cell Memory-like Conv T cells |
|
| Mean Difference (Final Values) |
| -1.54 |
| Standard Error of the Mean |
| 3.152 |
| 2-Sided |
| 95 |
| -8.12 |
| 5.03 |
The mean difference in Central Memory Conv T cells (Healthy participants versus NOT1D participants) in blood has been presented. |
| Other |
| Mean Difference (Final Values) | -0.23 | Standard Error of the Mean | 2.089 | 2-Sided | 95 | -4.59 | 4.13 | The mean difference in Effector Memory Conv T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | 0.92 | Standard Error of the Mean | 3.835 | 2-Sided | 95 | -7.08 | 8.92 | The mean difference in Naive Conv T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | -0.09 | Standard Error of the Mean | 0.145 | 2-Sided | 95 | -0.40 | 0.21 | The mean difference in Stem Cell Memory-like Conv T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Effector Memory Conv T cells |
|
| Naive Conv T cells |
|
| Stem Cell Memory-like Conv T cells |
|
| Mean Difference (Final Values) |
| -1.95 |
| Standard Error of the Mean |
| 3.943 |
| 2-Sided |
| 95 |
| -10.20 |
| 6.29 |
The mean difference in Central Memory Conv T cells (Healthy participants versus NOT1D participants) in iLN has been presented. |
| Other |
| Mean Difference (Final Values) | 2.15 | Standard Error of the Mean | 3.621 | 2-Sided | 95 | -5.38 | 9.69 | The mean difference in Effector Memory Conv T cells(Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | -0.80 | Standard Error of the Mean | 4.629 | 2-Sided | 95 | -10.47 | 8.86 | The mean difference in Naive Conv T cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | -0.21 | Standard Error of the Mean | 0.268 | 2-Sided | 95 | -0.77 | 0.34 | The mean difference in Stem cell Memory-like Conv T cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| PD-1+ ICOS+ TFH cells; n=6, 7 |
|
|
| TH17 cells; n=12, 10 |
|
|
| TH1 cells; n=12, 10 |
|
|
| TH1 TH17 cells; n=12, 10 |
|
|
| TH1 TH17 TH2 T cells; n=12, 10 |
|
|
| TH1 TH2 cells; n=12, 10 |
|
|
| TH2 cells; n=12, 10 |
|
|
| TH22 cells; n=12, 10 |
|
|
| Mean Difference (Final Values) |
| -0.04 |
| Standard Error of the Mean |
| 0.050 |
| 2-Sided |
| 95 |
| -0.15 |
| 0.07 |
The mean difference in PD-1+ ICOS+ TFH cells (Healthy participants versus NOT1D participants) in blood has been presented. |
| Other |
| Mean Difference (Final Values) | -0.10 | Standard Error of the Mean | 1.428 | 2-Sided | 95 | -3.08 | 2.88 | The mean difference in TH17 cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | 2.09 | Standard Error of the Mean | 4.294 | 2-Sided | 95 | -6.87 | 11.05 | The mean difference in TH1 cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | 0.03 | Standard Error of the Mean | 2.382 | 2-Sided | 95 | -4.94 | 5.00 | The mean difference in TH1 TH17 cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | 0.00 | Standard Error of the Mean | 1.112 | 2-Sided | 95 | -2.31 | 2.32 | The mean difference in TH1 TH17 TH2 T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | -0.59 | Standard Error of the Mean | 1.026 | 2-Sided | 95 | -2.73 | 1.55 | The mean difference in TH1 TH2 cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | 1.57 | Standard Error of the Mean | 1.474 | 2-Sided | 95 | -1.51 | 4.64 | The mean difference in TH2 cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | -0.00 | Standard Error of the Mean | 0.504 | 2-Sided | 95 | -1.05 | 1.05 | The mean difference in TH22 cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| PD-1+ ICOS+ TFH cells; n=10,10 |
|
|
| TH17 cells; n=12,10 |
|
|
| TH1 cells; n=12,10 |
|
|
| TH1 TH17 cells; n=11,10 |
|
|
| TH1 TH17 TH2 T cells; n=11,10 |
|
|
| TH1 TH2 cells; n=12,10 |
|
|
| TH2 cells; n=12,10 |
|
|
| TH22 cells; n=12,10 |
|
|
| Mean Difference (Final Values) |
| -0.62 |
| Standard Error of the Mean |
| 0.855 |
| 2-Sided |
| 95 |
| -2.43 |
| 1.18 |
The mean difference in PD-1+ ICOS+ TFH cells (Healthy participants versus NOT1D participants) in iLN has been presented. |
| Other |
| Mean Difference (Final Values) | 0.41 | Standard Error of the Mean | 1.391 | 2-Sided | 95 | -2.49 | 3.31 | The mean difference in TH17 cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | -3.50 | Standard Error of the Mean | 2.824 | 2-Sided | 95 | -9.39 | 2.39 | The mean difference in TH1 cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | 0.24 | Standard Error of the Mean | 0.738 | 2-Sided | 95 | -1.29 | 1.78 | The mean difference in TH1 TH17 cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | 0.40 | Standard Error of the Mean | 0.544 | 2-Sided | 95 | -0.73 | 1.54 | The mean difference in TH1 TH17 TH2 T cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | 0.48 | Standard Error of the Mean | 1.246 | 2-Sided | 95 | -2.12 | 3.07 | The mean difference in TH1 TH2 cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | 3.05 | Standard Error of the Mean | 2.641 | 2-Sided | 95 | -2.45 | 8.55 | The mean difference in TH2 cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | 0.02 | Standard Error of the Mean | 0.448 | 2-Sided | 95 | -0.92 | 0.96 | The mean difference in TH22 cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| PD-1+ ICOS+ TFH cells-like Reg T cells; n=0, 0 |
|
| TH1 cells-like Reg T cells; n=12, 10 |
|
|
| TH1 TH17-like Reg T cells; n=7, 7 |
|
|
| TH1 TH17 TH2 cells-like Reg T cells; n=12, 10 |
|
|
| TH1 TH2 cells-like Reg T cells; n=12, 10 |
|
|
| TH17 cells-like Reg T cells; n=12, 10 |
|
|
| TH2 cells-like Reg T cells; n=12, 10 |
|
|
| TH22 cells-like Reg T cells; n=12, 10 |
|
|
| Mean Difference (Final Values) |
| -0.83 |
| Standard Error of the Mean |
| 0.953 |
| 2-Sided |
| 95 |
| -2.82 |
| 1.16 |
The mean difference in TH1 cells-like Reg T cells (Healthy participants versus NOT1D participants) in blood has been presented. |
| Other |
| Mean Difference (Final Values) | -2.88 | Standard Error of the Mean | 1.536 | 95 | -6.08 | 0.33 | The mean difference in TH1 TH17 TH2 cells-like Reg T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | 1.81 | Standard Error of the Mean | 0.963 | 2-Sided | 95 | -0.20 | 3.81 | The mean difference in TH1 TH2 cells-like Reg T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | -0.30 | Standard Error of the Mean | 1.289 | 2-Sided | 95 | -2.99 | 2.39 | The mean difference in TH17 cells-like Reg T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | 3.38 | Standard Error of the Mean | 1.907 | 2-Sided | 95 | -0.59 | 7.36 | The mean difference in TH2 cells-like Reg T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | -1.16 | Standard Error of the Mean | 1.413 | 2-Sided | 95 | -4.11 | 1.78 | The mean difference in TH22 cells-like Reg T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| PD-1+ ICOS+ TFH cells-like Reg T cells; n=5,7 |
|
|
| TH1 cells-like Reg T cells; n=12, 10 |
|
|
| TH1 TH17-like Reg T cells; n=1, 2 |
|
|
| TH1 TH17 TH2 cells-like Reg T cells; n=7, 6 |
|
|
| TH1 TH2 cells-like Reg T cells; n=12, 10 |
|
|
| TH17 cells-like Reg T cells; n=12, 10 |
|
|
| TH2 cells-like Reg T cells; n=12, 10 |
|
|
| TH22 cells-like Reg T cells; n=8, 7 |
|
|
| Mean Difference (Final Values) |
| -4.10 |
| Standard Error of the Mean |
| 1.842 |
| 2-Sided |
| 95 |
| -7.93 |
| -0.26 |
The mean difference in TH1 cells-like Reg T cells (Healthy participants versus NOT1D participants) in iLN has been presented. |
| Other |
| Mean Difference (Final Values) | -1.55 | Standard Error of the Mean | 1.209 | 2-Sided | 95 | -4.34 | 1.24 | The mean difference in TH1 TH17 TH2 cells-like Reg T cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | -0.87 | Standard Error of the Mean | 1.725 | 2-Sided | 95 | -4.51 | 2.77 | The mean difference in TH1 TH2 cells-like Reg T cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | -0.47 | Standard Error of the Mean | 2.193 | 2-Sided | 95 | -5.02 | 4.09 | The mean difference in TH17 cells-like Reg T cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | 0.58 | Standard Error of the Mean | 3.405 | 2-Sided | 95 | -6.52 | 7.68 | The mean difference in TH2 cells-like Reg T cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | -0.41 | Standard Error of the Mean | 0.811 | 2-Sided | 95 | -2.21 | 1.40 | The mean difference in TH22 cells-like Reg T cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) |
| -0.83 |
| Standard Error of the Mean |
| 0.580 |
| 2-Sided |
| 95 |
| -2.04 |
| 0.38 |
The mean difference in Ki67+ CD8 cells (Healthy participants versus NOT1D participants) in blood has been presented. |
| Other |
| Ki67+ CD8 cells; n= 11, 6 |
|
|
| Mean Difference (Final Values) |
| 2.20 |
| Standard Error of the Mean |
| 1.051 |
| 2-Sided |
| 95 |
| -0.04 |
| 4.44 |
The mean difference in Ki67+ CD8 cells (Healthy participants versus NOT1D participants) in iLN has been presented. |
| Other |
| CD69+ Reg T cells; n= 11, 10 |
|
|
| Helios+ Reg T cells; n= 12, 10 |
|
|
| Ki67+ T Reg cells; n= 12, 10 |
|
|
| Memory Reg T cells; n= 12, 10 |
|
|
| Resting Reg T cells n= 12, 10 |
|
|
| Mean Difference (Final Values) |
| 0.92 |
| Standard Error of the Mean |
| 0.308 |
| 2-Sided |
| 95 |
| 0.28 |
| 1.57 |
The mean difference in CD69+ Reg T cells (Healthy participants versus NOT1D participants) in blood has been presented. |
| Other |
| Mean Difference (Final Values) | 4.21 | Standard Error of the Mean | 3.017 | 2-Sided | 95 | -2.08 | 10.51 | The mean difference in Helios+ Reg T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | -0.98 | Standard Error of the Mean | 0.985 | 2-Sided | 95 | -3.03 | 1.08 | The mean difference in Ki67+ T Reg cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | -4.86 | Standard Error of the Mean | 3.802 | 2-Sided | 95 | -12.80 | 3.07 | The mean difference in Memory Reg T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | 8.60 | Standard Error of the Mean | 4.733 | 2-Sided | 95 | -1.27 | 18.47 | The mean difference in Resting Reg T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| CD69+ Reg T cells; n= 11, 9 |
|
|
| Helios+ Reg T cells; n=11,9 |
|
|
| Ki67+ T Reg cell; n= 10, 8 |
|
|
| Memory Reg T cells; n= 11, 9 |
|
|
| Resting Reg T cells; n=11,9 |
|
|
| Mean Difference (Final Values) |
| -8.54 |
| Standard Error of the Mean |
| 4.595 |
| 2-Sided |
| 95 |
| -18.17 |
| 1.10 |
The mean difference in CD69+ Reg T cells (Healthy participants versus NOT1D participants) in blood has been presented. |
| Other |
| Mean Difference (Final Values) | 2.11 | Standard Error of the Mean | 2.519 | 2-Sided | 95 | -3.23 | 7.45 | The mean difference in Helios+ Reg T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | 3.30 | Standard Error of the Mean | 2.020 | 2-Sided | 95 | -0.98 | 7.59 | The mean difference in Ki67+ T Reg cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | 0.22 | Standard Error of the Mean | 4.026 | 2-Sided | 95 | -8.23 | 8.67 | The mean difference in Memory Reg T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | 8.31 | Standard Error of the Mean | 4.595 | 2-Sided | 95 | -1.32 | 17.95 | The mean difference in Resting Reg T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Helios+ Conv T cells |
|
| Ki67+ Conv T cells |
|
| Mean Difference (Final Values) |
| 0.64 |
| Standard Error of the Mean |
| 0.306 |
| 2-Sided |
| 95 |
| 0.00 |
| 1.28 |
The mean difference in CD69+ Conv T cells (Healthy participants versus NOT1D participants) in blood has been presented. |
| Other |
| Mean Difference (Final Values) | 0.39 | Standard Error of the Mean | 0.345 | 2-Sided | 95 | -0.33 | 1.11 | The mean difference in Helios+ Conv T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | -0.15 | Standard Error of the Mean | 0.300 | 2-Sided | 95 | -0.78 | 0.47 | The mean difference in Ki67+ Conv T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| CD69+ Conv T cells; n=11, 9 |
|
|
| Helios+ Conv T cells;n=11,9 |
|
|
| Ki67+ Conv T cells; n= 11,8 |
|
|
| Mean Difference (Final Values) |
| -2.55 |
| Standard Error of the Mean |
| 4.716 |
| 2-Sided |
| 95 |
| -12.45 |
| 7.35 |
The mean difference in CD69+ Conv T cells (Healthy participants versus NOT1D participants) in iLN has been presented. |
| Other |
| Mean Difference (Final Values) | 0.14 | Standard Error of the Mean | 0.957 | 2-Sided | 95 | -1.86 | 2.14 | The mean difference in Helios+ Conv T cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | 2.74 | Standard Error of the Mean | 0.872 | 2-Sided | 95 | 0.90 | 4.58 | The mean difference in Ki67+ Conv T cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Helios+ Memory Conv T cells |
|
| Ki67+ Memory Conv T cells |
|
| Mean Difference (Final Values) |
| 0.84 |
| Standard Error of the Mean |
| 0.351 |
| 2-Sided |
| 95 |
| 0.10 |
| 1.57 |
The mean difference in CD69+ Memory Conv T cells (Healthy participants versus NOT1D participants) in blood has been presented. |
| Other |
| Mean Difference (Final Values) | 0.83 | Standard Error of the Mean | 0.594 | 2-Sided | 95 | -0.41 | 2.07 | The mean difference in Helios+ Memory Conv T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| Mean Difference (Final Values) | -0.31 | Standard Error of the Mean | 0.589 | 2-Sided | 95 | -1.54 | 0.92 | The mean difference in Ki67+ Memory Conv T cells (Healthy participants versus NOT1D participants) in blood has been presented. | Other |
| CD69+ Memory Conv T cells; n=11, 9 |
|
|
| Helios+ Memory Conv T cells; n= 11, 9 |
|
|
| Ki67+ Memory Conv T cells; n=11,8 |
|
|
| Mean Difference (Final Values) |
| -2.06 |
| Standard Error of the Mean |
| 4.392 |
| 2-Sided |
| 95 |
| -11.33 |
| 7.21 |
The mean difference in CD69+ Memory Conv T cells (Healthy participants versus NOT1D participants) in iLN has been presented. |
| Other |
| Mean Difference (Final Values) | 1.28 | Standard Error of the Mean | 2.042 | 2-Sided | 95 | -14.56 | 17.13 | The mean difference in Helios+ Memory Conv T cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Mean Difference (Final Values) | 2.14 | Standard Error of the Mean | 0.843 | 2-Sided | 95 | 0.36 | 3.92 | The mean difference in Ki67+ Memory Conv T cells (Healthy participants versus NOT1D participants) in iLN has been presented. | Other |
| Circulating B Lymphocytes; Core; n=4, 8 |
|
|
| Classical B Lymphocytes; FNA; n=9,4 |
|
|
| Classical B Lymphocytes; Core; n= 4, 8 |
|
|
| Double Negative B Lymphocytes; FNA; n=9,4 |
|
|
| Double Negative B Lymphocytes; Core; n= 4, 8 |
|
|
| Naive B Lymphocytes;FNA; n=9,4 |
|
|
| Naive B Lymphocytes; Core; n= 4, 8 |
|
|
| Plasmablast; FNA; n=4, 3 |
|
|
| Plasmablast; Core; n=0, 5 |
|
|
| Transitional B Lymphocytes; FNA; n=2, 1 |
|
|
| Transitional B Lymphocytes;Core; n=1, 2 |
|
|
| Mean Difference (Final Values) |
| 4.46 |
| Standard Error of the Mean |
| 2.334 |
| 2-Sided |
| 95 |
| -0.47 |
| 9.39 |
The mean difference in Circulating B Lymphocytes (Healthy participants versus NOT1D participants) by core biopsy method has been presented. |
| Other |
| Mean Difference (Final Values) | 11.54 | Standard Error of the Mean | 7.693 | 2-Sided | 95 | -5.24 | 28.32 | The mean difference in Classical B Lymphocytes (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 5.64 | Standard Error of the Mean | 6.000 | 2-Sided | 95 | -7.73 | 19.01 | The mean difference in Classical B Lymphocytes (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -1.37 | Standard Error of the Mean | 3.336 | 2-Sided | 95 | -8.46 | 5.71 | The mean difference in Double Negative B Lymphocytes (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -1.78 | Standard Error of the Mean | 1.755 | 2-Sided | 95 | -5.54 | 1.98 | The mean difference in Double Negative B Lymphocytes (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -8.30 | Standard Error of the Mean | 6.080 | 2-Sided | 95 | -21.58 | 4.98 | The mean difference in Naive B Lymphocytes (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -8.31 | Standard Error of the Mean | 6.019 | 2-Sided | 95 | -21.49 | 4.87 | The mean difference in Naive B Lymphocytes by (Healthy participants versus NOT1D participants) core biopsy method has been presented. | Other |
| B-cells; Core; n=4, 8 |
|
|
| CD56+CD16+; FNA; n=8, 2 |
|
|
| CD56+CD16+; Core; n=2, 7 |
|
|
| CD56bright NK cells; FNA; n=9, 4 |
|
|
| CD56bright NK cells; Core; n=4, 8 |
|
|
| CD56lo CD16+; FNA; n=9, 4 |
|
|
| CD56lo CD16+; Core; n=3, 8 |
|
|
| CD56lo CD16-; FNA; n=8, 4 |
|
|
| CD56lo CD16-; Core; n=3,7 |
|
|
| Dendritic cells; FNA; n=9, 4 |
|
|
| Dendritic cells; Core; n=4, 8 |
|
|
| NK cells; FNA; n=9, 4 |
|
|
| NK cells; Core; n=4, 8 |
|
|
| Mean Difference (Final Values) |
| -1.88 |
| Standard Error of the Mean |
| 2.990 |
| 2-Sided |
| 95 |
| -8.37 |
| 4.61 |
The mean difference in B-cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. |
| Other |
| Mean Difference (Final Values) | 0.14 | Standard Error of the Mean | 0.189 | 2-Sided | 95 | -0.26 | 0.54 | The mean difference in CD56bright NK cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -0.05 | Standard Error of the Mean | 0.147 | 2-Sided | 95 | -0.37 | 0.27 | The mean difference in CD56bright NK cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -0.39 | Standard Error of the Mean | 0.402 | 2-Sided | 95 | -1.27 | 0.49 | The mean difference in CD56lo CD16+ (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 0.37 | Standard Error of the Mean | 0.312 | 2-Sided | 95 | -0.33 | 1.07 | The mean difference in CD56lo CD16+ (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -0.02 | Standard Error of the Mean | 0.068 | 2-Sided | 95 | -0.16 | 0.13 | The mean difference in CD56lo CD16- by (Healthy participants versus NOT1D participants) FNA method has been presented. | Other |
| Mean Difference (Final Values) | -0.03 | Standard Error of the Mean | 0.068 | 2-Sided | 95 | -0.17 | 0.12 | The mean difference in CD56lo CD16- (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | 0.22 | Standard Error of the Mean | 0.114 | 2-Sided | 95 | -0.03 | 0.47 | The mean difference in Dendritic cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -0.09 | Standard Error of the Mean | 0.221 | 2-Sided | 95 | -0.59 | 0.40 | The mean difference in Dendritic cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -0.06 | Standard Error of the Mean | 0.766 | 2-Sided | 95 | -1.72 | 1.60 | The mean difference in NK cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -0.08 | Standard Error of the Mean | 0.417 | 2-Sided | 95 | -0.99 | 0.82 | The mean difference in NK cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| CD56+CD16+; Core; n=2, 7 |
|
|
| CD56bright NK cells; FNA; n=9, 4 |
|
|
| CD56bright NK cells; Core; n=4, 8 |
|
|
| CD56lo CD16+; FNA; n=9, 4 |
|
|
| CD56lo CD16+; Core; n=3, 8 |
|
|
| CD56lo CD16-; FNA; n=8, 4 |
|
|
| CD56lo CD16-; Core; n=3, 7 |
|
|
| Mean Difference (Final Values) |
| -0.04 |
| Standard Error of the Mean |
| 7.566 |
| 2-Sided |
| 95 |
| -16.85 |
| 16.78 |
The mean difference in CD56bright NK cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. |
| Other |
| Mean Difference (Final Values) | -20.03 | Standard Error of the Mean | 8.586 | 2-Sided | 95 | -38.98 | -1.08 | The mean difference in CD56lo CD16+ (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 4.25 | Standard Error of the Mean | 12.739 | 2-Sided | 95 | -24.14 | 32.65 | The mean difference in CD56lo CD16+ by (Healthy participants versus NOT1D participants) core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -0.14 | Standard Error of the Mean | 2.429 | 2-Sided | 95 | -5.54 | 5.26 | The mean difference in CD56lo CD16- (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -2.79 | Standard Error of the Mean | 4.148 | 2-Sided | 95 | -12.31 | 6.73 | The mean difference in CD56lo CD16- (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Myeloid Dendritic cells; Core; n=4 ,8 |
|
|
| Plasmacytoid Dendritic cells; FNA; n=9, 3 |
|
|
| Plasmacytoid Dendritic cells; Core; n=4, 8 |
|
|
| Mean Difference (Final Values) |
| 16.22 |
| Standard Error of the Mean |
| 6.189 |
| 2-Sided |
| 95 |
| 3.17 |
| 29.26 |
The mean difference in Myeloid Dendritic cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. |
| Other |
| Mean Difference (Final Values) | -7.89 | Standard Error of the Mean | 10.509 | 2-Sided | 95 | -31.03 | 15.25 | The mean difference in Plasmacytoid Dendritic cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -13.85 | Standard Error of the Mean | 5.781 | 2-Sided | 95 | -26.04 | -1.66 | The mean difference in (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| CD14+ CD16+ monocytes; Core; n=0, 0 |
|
| CD14+ monocytes; ;FNA; n=5, 2 |
|
|
| CD14+ monocytes;Core; n=3, 3 |
|
|
| CD16+ monocytes; ;FNA; n=0, 2 |
|
|
| CD16+ monocytes; ;FNA; n=0,0 |
|
| CD45RA+ Effector Memory CD8; Core; n=11, 10 |
|
|
| Central Memory CD8; FNA; n=12, 7 |
|
|
| Central Memory CD8; Core; n=11, 10 |
|
|
| Effector Memory CD8; FNA; n=12, 8 |
|
|
| Effector Memory CD8; Core; n= 11, 10 |
|
|
| Naive CD8; FNA; n=12, 8 |
|
|
| Naive CD8; Core; n=11, 10 |
|
|
| Stem Cell Memory-like CD8;FNA; n= 12, 6 |
|
|
| Stem Cell Memory-like CD8; Core; 9,10 |
|
|
| Mean Difference (Final Values) |
| 4.01 |
| Standard Error of the Mean |
| 3.418 |
| 2-Sided |
| 95 |
| -3.13 |
| 11.16 |
The mean difference in CD45RA+ Effector Memory CD8 cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. |
| Other |
| Mean Difference (Final Values) | -0.16 | Standard Error of the Mean | 1.428 | 2-Sided | 95 | -3.14 | 2.82 | The mean difference in Central Memory CD8 cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -1.16 | Standard Error of the Mean | 1.851 | 2-Sided | 95 | -5.03 | 2.71 | The mean difference in Central Memory CD8 cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -2.11 | Standard Error of the Mean | 3.132 | 2-Sided | 95 | -8.65 | 4.43 | The mean difference in Effector Memory CD8 cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -1.59 | Standard Error of the Mean | 3.071 | 2-Sided | 95 | -8.00 | 4.81 | The mean difference in Effector Memory CD8 cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | 3.51 | Standard Error of the Mean | 6.594 | 2-Sided | 95 | -10.21 | 17.24 | The mean difference in Naive CD8 cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -2.18 | Standard Error of the Mean | 7.155 | 2-Sided | 95 | -17.10 | 12.74 | The mean difference in Naive CD8 cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -0.92 | Standard Error of the Mean | 0.708 | 2-Sided | 95 | -2.42 | 0.58 | The mean difference in Stem Cell Memory-like CD8 cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -0.42 | Standard Error of the Mean | 0.372 | 2-Sided | 95 | -1.19 | 0.35 | The mean difference in Stem Cell Memory-like CD8 cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| PD-1+ ICOS+ TFH cell-like Reg T cells; Core; n=4,5 |
|
|
| PD-1+ ICOS+ TFH cells; Core; n=6, 10 |
|
|
| Mean Difference (Final Values) |
| -7.03 |
| Standard Error of the Mean |
| 7.114 |
| 2-Sided |
| 95 |
| -22.22 |
| 8.16 |
The mean difference in PD-1+ ICOS+ TFH cells (Healthy participants versus NOT1D participants) by core biopsy FNA method has been presented. |
| Other |
| CD45RA+ Effector Memory Conv T cells;Core;n=11, 10 |
|
|
| Central Memory Conv T cells; FNA; n= 12, 8 |
|
|
| Central Memory Conv T cells; Core; n= 11, 10 |
|
|
| Effector Memory Conv T cells; FNA; n=12, 8 |
|
|
| Effector Memory Conv T cells; Core; n=11, 10 |
|
|
| Naive Conv T cells; FNA; n=12,8 |
|
|
| Naive Conv T cells; Core; n=11, 10 |
|
|
| Stem Cell Memory-like Conv T cells; FNA; n=12, 7 |
|
|
| Stem Cell Memory-like Conv T cells; Core; n=11, 10 |
|
|
| Mean Difference (Final Values) |
| 0.13 |
| Standard Error of the Mean |
| 0.184 |
| 2-Sided |
| 95 |
| -0.25 |
| 0.52 |
The mean difference in CD45RA+ Effector Memory Conv T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. |
| Other |
| Mean Difference (Final Values) | -0.19 | Standard Error of the Mean | 4.220 | 2-Sided | 95 | -9.02 | 8.64 | The mean difference in Central Memory Conv T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -3.72 | Standard Error of the Mean | 4.223 | 2-Sided | 95 | -12.57 | 5.13 | The mean difference in Central Memory Conv T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | 2.25 | Standard Error of the Mean | 4.034 | 2-Sided | 95 | -6.16 | 10.66 | The mean difference in Effector Memory Conv T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 2.06 | Standard Error of the Mean | 3.994 | 2-Sided | 95 | -6.27 | 10.39 | The mean difference in Effector Memory Conv T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -2.09 | Standard Error of the Mean | 5.727 | 2-Sided | 95 | -14.09 | 9.92 | The mean difference in Naive Conv T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 0.48 | Standard Error of the Mean | 4.976 | 2-Sided | 95 | -9.91 | 10.87 | The mean difference in Naive Conv T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -0.01 | Standard Error of the Mean | 0.314 | 2-Sided | 95 | -0.67 | 0.65 | The mean difference in Stem Cell Memory-like Conv T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -0.42 | Standard Error of the Mean | 0.325 | 2-Sided | 95 | -1.10 | 0.26 | The mean difference in Stem Cell Memory-like Conv T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| TFH cells; Core; n=11,10 |
|
|
| PD-1+ ICOS+ TFH cells; FNA; n=8,4 |
|
|
| PD-1+ ICOS+ TFH cells; Core; n=6,10 |
|
|
| TH17 cells;FNA; n=12,8 |
|
|
| TH17 cells; Core; n=11,10 |
|
|
| TH1 cells; FNA; n=12,8 |
|
|
| TH1 cells; Core; n=11,10 |
|
|
| TH1 TH17 cells; FNA; n=10,4 |
|
|
| TH1 TH17 cells; Core; n=10,10 |
|
|
| TH1 TH17 TH2 T cells; FNA; n=10,4 |
|
|
| TH1 TH17 TH2 T cells; Core; n=10,10 |
|
|
| TH1 TH2 cells; FNA; n=12,6 |
|
|
| TH1 TH2 cells; Core; n=10, 10 |
|
|
| TH2 cells; FNA; n=12,8 |
|
|
| TH2 cells; Core; n=11,10 |
|
|
| TH22 cells; FNA; n=12,4 |
|
|
| TH22 cells; Core; n=10, 10 |
|
|
| Mean Difference (Final Values) |
| -3.93 |
| Standard Error of the Mean |
| 4.828 |
| 2-Sided |
| 95 |
| -14.02 |
| 6.17 |
The mean difference in TFH cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. |
| Other |
| Mean Difference (Final Values) | -1.26 | Standard Error of the Mean | 0.651 | 2-Sided | 95 | -2.69 | 0.16 | The mean difference in PD-1+ ICOS+ TFH cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 0.01 | Standard Error of the Mean | 1.507 | 2-Sided | 95 | -3.21 | 3.24 | The mean difference in PD-1+ ICOS+ TFH cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | 0.77 | Standard Error of the Mean | 1.709 | 2-Sided | 95 | -2.78 | 4.33 | The mean difference in TH17 cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 0.05 | Standard Error of the Mean | 1.339 | 2-Sided | 95 | -2.75 | 2.85 | The mean difference in TH17 cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -0.97 | Standard Error of the Mean | 3.631 | 2-Sided | 95 | -8.56 | 6.63 | The mean difference in TH1 cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -6.03 | Standard Error of the Mean | 2.708 | 2-Sided | 95 | -11.69 | -0.38 | The mean difference in TH1 cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -0.10 | Standard Error of the Mean | 0.889 | 2-Sided | 95 | -1.98 | 1.78 | The mean difference in TH1 TH17 cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 0.59 | Standard Error of the Mean | 0.787 | 2-Sided | 95 | -1.07 | 2.24 | The mean difference in TH1 TH17 cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | 0.43 | Standard Error of the Mean | 0.613 | 2-Sided | 95 | -0.85 | 1.72 | The mean difference in TH1 TH17 TH2 T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 0.38 | Standard Error of the Mean | 0.565 | 2-Sided | 95 | -0.80 | 1.56 | The mean difference in TH1 TH17 TH2 T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | 0.53 | Standard Error of the Mean | 1.546 | 2-Sided | 95 | -2.71 | 3.76 | The mean difference in TH1 TH2 cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 0.42 | Standard Error of the Mean | 1.610 | 2-Sided | 95 | -2.95 | 3.79 | The mean difference in TH1 TH2 cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | 2.15 | Standard Error of the Mean | 3.356 | 2-Sided | 95 | -4.84 | 9.14 | The mean difference in TH2 cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 3.95 | Standard Error of the Mean | 2.481 | 2-Sided | 95 | -1.25 | 9.15 | The mean difference in TH2 cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | 0.05 | Standard Error of the Mean | 0.627 | 2-Sided | 95 | -1.28 | 1.38 | The mean difference in TH22 cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -0.01 | Standard Error of the Mean | 0.438 | 2-Sided | 95 | -0.93 | 0.91 | The mean difference in TH22 cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| TFH cells-like Reg T cells; Core; n=9, 10 |
|
|
| PD-1+ ICOS+ TFH cells-like Reg T cells;FNA;n=2,3 |
|
|
| PD-1+ ICOS+ TFH cells-like Reg T cells;Core;n=4,5 |
|
|
| TH1 cells-like Reg T cells;FNA; n=11,5 |
|
|
| TH1 cells-like Reg T cells;Core;n=8, 10 |
|
|
| TH1 TH17-like Reg T cells;FNA; n=1, 1 |
|
|
| TH1 TH17-like Reg T cells;Core; n=0,2 |
|
|
| TH1 TH17 TH2 cells-like Reg T cells;FNA; n=7, 4 |
|
|
| TH1 TH17 TH2 cells-like Reg T cells;Core;n=5,5 |
|
|
| TH1 TH2 cells-like Reg T cells;FNA; n=11, 4 |
|
|
| TH1 TH2 cells-like Reg T cells;Core; n=10,10 |
|
|
| TH17 cells-like Reg T cells;FNA; n=11, 4 |
|
|
| TH17 cells-like Reg T cells;Core; n=10, 10 |
|
|
| TH2 cells-like Reg T cells;FNA; n=12, 8 |
|
|
| TH2 cells-like Reg T cells;Core; n=11, 10 |
|
|
| TH22 cells-like Reg T cells;FNA; n=6,3 |
|
|
| TH22 cells-like Reg T cells;Core; n=7,7 |
|
|
| Mean Difference (Final Values) |
| 0.72 |
| Standard Error of the Mean |
| 2.694 |
| 2-Sided |
| 95 |
| -4.90 |
| 6.35 |
The mean difference in TFH cells-like Reg T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. |
| Other |
| Mean Difference (Final Values) | -4.90 | Standard Error of the Mean | 2.377 | 2-Sided | 95 | -9.89 | 0.08 | The mean difference in TH1 cells-like Reg T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -3.29 | Standard Error of the Mean | 1.682 | 2-Sided | 95 | -6.82 | 0.24 | The mean difference in TH1 cells-like Reg T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -0.29 | Standard Error of the Mean | 1.036 | 2-Sided | 95 | -2.67 | 2.10 | The mean difference in TH1 TH17 TH2 cells-like Reg T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -2.80 | Standard Error of the Mean | 1.929 | 2-Sided | 95 | -7.20 | 1.59 | The mean difference in TH1 TH17 TH2 cells-like Reg T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -1.44 | Standard Error of the Mean | 2.117 | 2-Sided | 95 | -5.98 | 3.11 | The mean difference in TH1 TH2 cells-like Reg T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -0.30 | Standard Error of the Mean | 2.047 | 2-Sided | 95 | -4.59 | 3.99 | The mean difference in TH1 TH2 cells-like Reg T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -1.47 | Standard Error of the Mean | 2.645 | 2-Sided | 95 | -6.99 | 4.06 | The mean difference in TH17 cells-like Reg T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 0.53 | Standard Error of the Mean | 2.185 | 2-Sided | 95 | -4.05 | 5.11 | The mean difference in TH17 cells-like Reg T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -2.25 | Standard Error of the Mean | 4.299 | 2-Sided | 95 | -11.23 | 6.73 | The mean difference in TH2 cells-like Reg T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 3.42 | Standard Error of the Mean | 3.472 | 2-Sided | 95 | -3.84 | 10.67 | The mean difference in TH2 cells-like Reg T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -0.65 | Standard Error of the Mean | 1.153 | 2-Sided | 95 | -3.30 | 2.00 | The mean difference in TH22 cells-like Reg T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -0.17 | Standard Error of the Mean | 0.869 | 2-Sided | 95 | -2.06 | 1.72 | The mean difference in TH22 cells-like Reg T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Reg T cells; Core; n=5, 9 |
|
|
| Mean Difference (Final Values) |
| -0.94 |
| Standard Error of the Mean |
| 1.056 |
| 2-Sided |
| 95 |
| -3.24 |
| 1.36 |
The mean difference in Reg T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. |
| Other |
| CD69+ CD8 cells; Core; n=5, 9 |
|
|
| Ki67+ CD8 cells; FNA; n=9, 3 |
|
|
| Ki67+ CD8 cells; Core; n=4, 6 |
|
|
| Mean Difference (Final Values) |
| -4.38 |
| Standard Error of the Mean |
| 5.301 |
| 2-Sided |
| 95 |
| -15.85 |
| 7.10 |
The mean difference in CD69+ CD8 cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. |
| Other |
| Mean Difference (Final Values) | 1.48 | Standard Error of the Mean | 1.374 | 2-Sided | 95 | -1.62 | 4.59 | The mean difference in Ki67+ CD8 cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 2.91 | Standard Error of the Mean | 1.291 | 2-Sided | 95 | -0.05 | 5.88 | The mean difference in Ki67+ CD8 cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| CD15s+ Reg T cells; Core; n=4, 8 |
|
|
| CD69+ Reg T cells; FNA; n=10, 4 |
|
|
| CD69+ Reg T cells; Core; n=5, 9 |
|
|
| Helios+ Reg T cells; FNA; n=10, 4 |
|
|
| Helios+ Reg T cells; Core; n=5, 9 |
|
|
| Ki67+ T Reg cells; FNA; n=8, 4 |
|
|
| Ki67+ T Reg cells; Core; n=4, 7 |
|
|
| Memory Reg T cells; FNA; n=10, 4 |
|
|
| Memory Reg T cells; Core; n=5, 9 |
|
|
| Resting Reg T cells; FNA; n=9, 4 |
|
|
| Resting Reg T cells; Core; n=5, 9 |
|
|
| Mean Difference (Final Values) |
| 8.21 |
| Standard Error of the Mean |
| 6.780 |
| 2-Sided |
| 95 |
| -6.15 |
| 22.57 |
The mean difference in CD15s+ Reg T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. |
| Other |
| Mean Difference (Final Values) | -11.19 | Standard Error of the Mean | 5.812 | 2-Sided | 95 | -23.48 | 1.11 | The mean difference in CD69+ Reg T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -5.89 | Standard Error of the Mean | 3.855 | 2-Sided | 95 | -14.14 | 2.37 | The mean difference in CD69+ Reg T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | 1.65 | Standard Error of the Mean | 2.480 | 2-Sided | 95 | -3.54 | 6.84 | The mean difference in Helios+ Reg T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 2.57 | Standard Error of the Mean | 2.937 | 2-Sided | 95 | -3.84 | 8.98 | The mean difference in Helios+ Reg T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | 3.22 | Standard Error of the Mean | 2.781 | 2-Sided | 95 | -2.67 | 9.12 | The mean difference in Ki67+ T Reg cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 3.38 | Standard Error of the Mean | 1.337 | 2-Sided | 95 | 0.55 | 6.21 | The mean difference in Ki67+ T Reg cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -1.45 | Standard Error of the Mean | 4.736 | 2-Sided | 95 | -11.49 | 8.58 | The mean difference in Memory Reg T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 1.88 | Standard Error of the Mean | 4.142 | 2-Sided | 95 | -6.81 | 10.58 | The mean difference in Memory Reg T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | 10.45 | Standard Error of the Mean | 5.790 | 2-Sided | 95 | -2.01 | 22.92 | The mean difference in Resting Reg T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 6.17 | Standard Error of the Mean | 4.913 | 2-Sided | 95 | -4.24 | 16.59 | The mean difference in Resting Reg T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| CD15s+ Conv T cells; Core; n=5, 8 |
|
|
| CD69+ Conv T cells;FNA;n=10, 4 |
|
|
| CD69+ Conv T cells; Core; n=5, 9 |
|
|
| Helios+ Conv T cells ; FNA;n=10, 4 |
|
|
| Helios+ Conv T cells ; Core; n=5, 9 |
|
|
| Ki67+ Conv T cells; FNA;n=9, 4 |
|
|
| Ki67+ Conv T cells ; Core; n=5, 8 |
|
|
| Mean Difference (Final Values) |
| 2.19 |
| Standard Error of the Mean |
| 1.324 |
| 2-Sided |
| 95 |
| -0.61 |
| 4.98 |
The mean difference in CD15s+ Conv T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. |
| Other |
| Mean Difference (Final Values) | -0.91 | Standard Error of the Mean | 6.389 | 2-Sided | 95 | -14.66 | 12.85 | The mean difference in CD69+ Conv T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -4.19 | Standard Error of the Mean | 4.862 | 2-Sided | 95 | -14.71 | 6.33 | The mean difference in CD69+ Conv T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | -0.13 | Standard Error of the Mean | 1.234 | 2-Sided | 95 | -2.73 | 2.47 | The mean difference in Helios+ Conv T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 0.41 | Standard Error of the Mean | 0.859 | 2-Sided | 95 | -1.45 | 2.28 | The mean difference in Helios+ Conv T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | 3.21 | Standard Error of the Mean | 1.205 | 2-Sided | 95 | 0.64 | 5.78 | The mean difference in Ki67+ Conv T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 2.27 | Standard Error of the Mean | 0.712 | 2-Sided | 95 | 0.75 | 3.79 | The mean difference in Ki67+ Conv T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| CD15s+ Memory Conv T cells; Core; n=5, 8 |
|
|
| CD69+ Memory Conv T cells; FNA; n=10, 4 |
|
|
| CD69+ Memory Conv T cells; Core; n=5, 9 |
|
|
| Helios+ Memory Conv T cells; FNA; n=9, 4 |
|
|
| Helios+ Memory Conv T cells; Core; n=5, 9 |
|
|
| Ki67+ Memory Conv T cells; FNA; n=9, 4 |
|
|
| Ki67+ Memory Conv T cells; Core; n=4, 8 |
|
|
| Mean Difference (Final Values) |
| 2.74 |
| Standard Error of the Mean |
| 2.109 |
| 2-Sided |
| 95 |
| -1.68 |
| 7.17 |
The mean difference in CD15s+ Memory Conv T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. |
| Other |
| Mean Difference (Final Values) | -0.00 | Standard Error of the Mean | 6.712 | 2-Sided | 95 | -14.49 | 14.48 | The mean difference in CD69+ Memory Conv T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | -4.12 | Standard Error of the Mean | 3.947 | 2-Sided | 95 | -12.67 | 4.43 | The mean difference in CD69+ Memory Conv T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | 1.33 | Standard Error of the Mean | 2.967 | 2-Sided | 95 | -5.48 | 8.13 | The mean difference in Helios+ Memory Conv T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 1.24 | Standard Error of the Mean | 2.287 | 2-Sided | 95 | -4.36 | 6.84 | The mean difference in Helios+ Memory Conv T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Mean Difference (Final Values) | 2.69 | Standard Error of the Mean | 1.019 | 2-Sided | 95 | 0.54 | 4.84 | The mean difference in Ki67+ Memory Conv T cells (Healthy participants versus NOT1D participants) by FNA method has been presented. | Other |
| Mean Difference (Final Values) | 1.58 | Standard Error of the Mean | 0.737 | 2-Sided | 95 | 0.03 | 3.13 | The mean difference in Ki67+ Memory Conv T cells (Healthy participants versus NOT1D participants) by core biopsy method has been presented. | Other |
| Honorarium |
|
| Other |
|
| All reasons |
|
| After-care |
|
| None |
|
| Other |
|